When to Start a Statin Is a Preference-Sensitive Decision.
作者信息
Hayward Rodney A
机构信息
From Departments of Internal Medicine & Health Management and Policy, University of Michigan, Ann Arbor, MI; and Department of Veterans Affairs (VA) HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, MI.
出版信息
Circulation. 2017 Sep 19;136(12):1099-1101. doi: 10.1161/CIRCULATIONAHA.117.029808.
Abstract
摘要
相似文献
1
When to Start a Statin Is a Preference-Sensitive Decision.何时开始使用他汀类药物是一个受偏好影响的决策。
Circulation. 2017 Sep 19;136(12):1099-1101. doi: 10.1161/CIRCULATIONAHA.117.029808.
2
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.评估他汀类药物用于冠心病和中风一级预防指南的影响及成本效益。
Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.
3
Statins and the Classic Decision Analysis: Treat, Test, or Neither?他汀类药物与经典决策分析：治疗、检测还是都不做？
Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004688. doi: 10.1161/CIRCOUTCOMES.118.004688.
4
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.他汀类药物治疗对冠心病一级预防的成本效益
Ir Med J. 2006 May;99(5):144-5.
5
Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.高剂量他汀类药物治疗对高危冠心病患者的增量获益及成本效益分析
Circulation. 2007 May 8;115(18):2398-409. doi: 10.1161/CIRCULATIONAHA.106.667683. Epub 2007 Apr 23.
6
Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.他汀类药物治疗对老年人心血管疾病一级预防的长期成本效益
Cardiovasc Drugs Ther. 2015 Apr;29(2):187-97. doi: 10.1007/s10557-015-6584-7.
7
Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.他汀类药物治疗在真实世界依从性条件下的初级预防的成本效益——来自芬兰处方登记处的估计。
Atherosclerosis. 2015 Mar;239(1):240-7. doi: 10.1016/j.atherosclerosis.2014.12.059. Epub 2015 Jan 14.
8
Statins for cardiovascular prevention according to different strategies: a cost analysis.根据不同策略的他汀类药物用于心血管预防的成本分析。
Am J Cardiovasc Drugs. 2011;11(1):33-44. doi: 10.2165/11586760-000000000-00000.
9
Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?HMG辅酶还原酶抑制剂的成本效益；该治疗谁？
Eur Heart J. 2001 May;22(9):751-61. doi: 10.1053/euhj.2000.2308.
10
[Statins in primary prevention: how to share the decision?].[他汀类药物用于一级预防：如何共同做出决策？]
Rev Med Suisse. 2015 Nov 25;11(496):2222-6.
引用本文的文献
1
The Need for Brevity During Shared Decision Making (SDM) for Cancer Screening: Veterans' Perspectives on an "Everyday SDM" Compromise.癌症筛查共同决策（SDM）过程中对简洁性的需求：退伍军人对“日常SDM”折衷方案的看法。
MDM Policy Pract. 2021 Oct 26;6(2):23814683211055120. doi: 10.1177/23814683211055120. eCollection 2021 Jul-Dec.
2
Guideline Concordance of Statin Treatment Decisions: A Retrospective Cohort Study.他汀类药物治疗决策的指南一致性：一项回顾性队列研究。
J Clin Med. 2020 Nov 19;9(11):3719. doi: 10.3390/jcm9113719.
本文引用的文献
1
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.评估他汀类药物用于冠心病和中风一级预防指南的影响及成本效益。
Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.
2
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.新研究并未对美国心脏病学会/美国心脏协会血脂指南构成挑战。
Ann Intern Med. 2016 Dec 6;165(11):827-828. doi: 10.7326/L16-0417.
3
A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention.一项关于心血管病一级预防中早期治疗升高的低密度脂蛋白相关临床证据的综述。
Evid Based Med. 2015 Oct;20(5):162-9. doi: 10.1136/ebmed-2015-110170. Epub 2015 Jul 14.
4
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.用于心血管疾病一级预防的他汀类药物治疗起始的10年风险阈值的成本效益
JAMA. 2015 Jul 14;314(2):142-50. doi: 10.1001/jama.2015.6822.
5
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.2型糖尿病患者的风险和偏好对降低血糖水平所获健康收益的影响。
JAMA Intern Med. 2014 Aug;174(8):1227-34. doi: 10.1001/jamainternmed.2014.2894.
6
Moneyball, gambling, and the new cholesterol guidelines.《点球成金》、赌博与新的胆固醇指南。
Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):311-4. doi: 10.1161/CIRCOUTCOMES.114.000876. Epub 2014 Mar 4.
7
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.每日服用阿司匹林治疗对个体和人群的益处：个性化国家指南的建议
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):268-75. doi: 10.1161/CIRCOUTCOMES.110.959239. Epub 2011 Apr 12.
8
Optimizing statin treatment for primary prevention of coronary artery disease.优化他汀类药物治疗以预防冠心病
Ann Intern Med. 2010 Jan 19;152(2):69-77. doi: 10.7326/0003-4819-152-2-201001190-00004.
9
The relative merits of population-based and targeted prevention strategies.基于人群的预防策略和针对性预防策略的相对优点。
Milbank Q. 2008 Dec;86(4):557-80. doi: 10.1111/j.1468-0009.2008.00534.x.
10
Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options.临床决策：从理论到实践。制定实践策略。标准、指南与选择。
JAMA. 1990 Jun 13;263(22):3077, 3081, 3084. doi: 10.1001/jama.263.22.3077.
Zotero 插件